Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the founders in connection with Polaris’ investment in Distriktstandvården
Mandate

Vinge advises the founders in connection with Polaris’ investment in Distriktstandvården

September 01, 2020 Employment and Benefits M&A

Vinge advises the founders of Distriktstandvården Ibbe Gnem and Jan Lindqvist in connection with Polaris’ investment in the company.

Distriktstandvården is the leading independent private dentistry chain in the greater Stockholm region. In addition to general, emergency and aesthetic dentistry services, Distriktstandvården offers specialist dental care as well as mobile and anaesthesia treatments. Following the investment, Polaris becomes a co-owner of Distriktstandvården alongside its founders who founded the company in 2010.

Vinge’s team consisted of Jonas Johansson, Matthias Pannier, Carl Sander, Nina Gransäter and Hanna Risberg (M&A), Ebba Svenburg (Employment), and VDR-specialists Jessica Öijer and Christoffer Widström.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025